top of page
ABOUT US
Innovators
Metabolica Health is a preclinical biotech company developing a first-in-class, oral therapy for diabetes, obesity, and metabolic liver disease. Our approach is rooted in the microbiome: we’re advancing a small molecule, 4-cresol, that restores the body’s ability to produce insulin and rebalance metabolism.
​
Unlike current treatments that manage symptoms, we target the biological root of disease — with regenerative effects on the insulin-producing pancreatic β-cells and broader benefits across systemic metabolism.
​
Backed by peer-reviewed publications, a granted U.S. patent, and global academic partnerships, Metabolica is building a scalable therapeutic platform with broad clinical potential and clear translational focus.
​
Our leadership team combines deep scientific expertise with operational and business experience to translate discovery into real-world impact.
MANAGEMENT
Howard Fields
CEO & President
Mr. Fields brings decades of entrepreneurial business experience along with with a background in sciences including undergraduate studies in biochemistry, biology and chemistry and graduate studies at USC Medical School pursuing a MD and a Ph.D. in pharmacology. He both founded and led several companies successfully in the US and Canada including global operations.
n the US
Scott Jardin, CPA, CGA
Chief Financial Officer
Mr. Jardin is a seasoned financial executive with experience across biotech, regulated consumer health, and academic research. He currently serves as CFO of The Good Shroom Co. and Teonan Biomedical, and previously led AAA Medic Montreal as CEO. He also managed finance operations for McGill University’s research centres. He holds a B.Comm from Concordia University and graduate diplomas in Finance and IT from McGill and UQAM.
​
Daniel Auld, Ph.D.
Chief Science Officer, EVP
Dr. Auld brings over 20 years of experience in neuroscience, drug development, and institutional leadership. He has co-led operations at McGill’s Victor Phillip Dahdaleh Institute of Genomic Medicine since 2011, holds two patents, and is a graduate of the adMare Executive Institute. He earned his Ph.D. from McGill and has published in journals including Nature.
​
Scott Jardin, CPA, CGA
Chief Financial Officer
Mr. Jardin is a seasoned financial executive with experience across biotech, regulated consumer health, and academic research. He currently serves as CFO of The Good Shroom Co. and Teonan Biomedical, and previously led AAA Medic Montreal as CEO. He also managed finance operations for McGill University’s research centres. He holds a B.Comm from Concordia University and graduate diplomas in Finance and IT from McGill and UQAM.
​
SCIENCTISTS
Scott Jardin, CPA, CGA
Chief Financial Officer
Mr. Jardin is a seasoned financial executive with experience across biotech, regulated consumer health, and academic research. He currently serves as CFO of The Good Shroom Co. and Teonan Biomedical, and previously led AAA Medic Montreal as CEO. He also managed finance operations for McGill University’s research centres. He holds a B.Comm from Concordia University and graduate diplomas in Finance and IT from McGill and UQAM.
​
Graham Wood, Ph.D.
Dr. Wood is a distinguished expert in clinical pharmacology with extensive leadership in biotech and pharmaceutical companies. He currently serves as Executive Vice-President of Nucleus Network (U.S.), overseeing U.S. operations and services. Dr. Wood excelled at McGill University, earning his Ph.D. in Neurology and Neurosurgery where he ranked first among doctoral students in Quebec and received numerous prestigious awards. He also holds an Hon. B.Sc. in Biochemistry, graduating Summa cum laude from McMaster University in 1994. He also holds an Hon. B.Sc. in Biochemistry, graduating Summa cum laude from McMaster University in 1994.
Dominique Gauguier, Ph.D.
Scientific Advisor/ Professor, Université Paris-CitéDr. Gauguier is an internationally recognized expert in metabolic disease genetics and a pioneer in the discovery of 4-cresol’s therapeutic potential. He is Director of Research at INSERM (Université Paris–Cité), and holds visiting and adjunct positions at Imperial College London, Kyoto University, and McGill University. He earned his Ph.D. in human nutrition in Paris and previously served as Professor of Mammalian Genetics at the University of Oxford.
BOARD OF DIRECTORS
Howard Fields
CEO & President
Mr. Fields brings decades of entreprenurial business experience along with with a background in sciences including undergraduate studies in biochemistry, biology and chemistry and graduate studies at USC Medical School pursuing a MD and a Ph.D. in pharmacology. He both founded and led several companies successfully in the US and Canada including global operations.
n the US
Roy Bonnel
Executive Chairman & Director
Mr. Bonnell brings over 30 years of leadership in capital markets, natural resources, and venture investment. He holds an LL.B. from Western University, an MSc from the London School of Economics, and an MBA from McGill. He is a member of the Law Society of Upper Canada.
​
Howard Fields
CEO & President
Mr. Fields brings decades of entrepreneurial business experience along with with a background in life sciences. He has both founded and successfully led companies in the US and Canada which included regulatory and global business practices. Mr. Fields has served on boards in the US and Canada.
Daniel Auld, Ph.D.
Director
Dr. Auld brings over 20 years of experience in neuroscience, drug development, and institutional leadership. He has co-led operations at McGill’s Victor Phillip Dahdaleh Institute of Genomic Medicine since 2011 and is a graduate of the adMare Executive Institute.
​
CAREERS
Join Us
As a growing Biotechnology Startup, we are always looking for new team members. Whether you’re interested in business or have something innovative and unique to bring to the table, we’d love to see if you’re a good fit for Metabolica Health. Send us your CV today to and we will get back to you as soon as we can.
bottom of page